← Leaderboards
Bryan William Davies
University Of Texas At Austin
$7,960,596
Attributed
$7,960,596
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,960,596 · 6
By mechanism
R01$6,390,445 · 3
R21$843,975 · 2
R56$726,176 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas At Austin
Same institution · by research overlap
- Renee Fleeman$922,607
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventBacteriaAntibioticsPathogenScreeningAntimicrobialAntimicrobial PeptideMulti-Drug ResistancePeptidesBindingInfectionFutureMolecularPathogenic BacteriaAnti-Bacterial AgentsBaseScaffoldMolecular TargetQuantumBackChemistryBacterial InfectionsFailureAntimicrobial Drug
Grant awards (16)
Vibrio microcins. A hidden field of targeted anti-cholerae natural products.$744,990
R01 · FY2025 · AI · contact PI
Vibrio microcins. A hidden field of targeted anti-cholerae natural products.$766,056
R01 · FY2024 · AI · contact PI
From microcin sequence to function: linking sequence variation to antimicrobial activity$726,176
R56 · FY2024 · AI · contact PI
Investigating nanobodies to target multidrug resistant bacterial pathogens$686,587
R01 · FY2023 · AI · contact PI
Investigating nanobodies to target multidrug resistant bacterial pathogens$686,587
R01 · FY2022 · AI · contact PI
Investigation of capsule interactions that promote antimicrobial peptide activity$234,240
R21 · FY2022 · AI · contact PI
Investigating nanobodies to target multidrug resistant bacterial pathogens$686,587
R01 · FY2021 · AI · contact PI
Investigation of capsule interactions that promote antimicrobial peptide activity$194,615
R21 · FY2021 · AI · contact PI
Investigating nanobodies to target multidrug resistant bacterial pathogens$784,687
R01 · FY2020 · AI · contact PI
A High-Throughput Molecular Platform for Antimicrobial Discovery and Study$404,429
R01 · FY2020 · AI · contact PI
A High-Throughput Molecular Platform for Antimicrobial Discovery and Study$404,429
R01 · FY2019 · AI · contact PI
Controlling the Virulence Genome of V. cholerae$225,710
R21 · FY2019 · AI · contact PI
A High-Throughput Molecular Platform for Antimicrobial Discovery and Study$404,429
R01 · FY2018 · AI · contact PI
Controlling the Virulence Genome of V. cholerae$189,410
R21 · FY2018 · AI · contact PI
A High-Throughput Molecular Platform for Antimicrobial Discovery and Study$404,429
R01 · FY2017 · AI · contact PI
A High-Throughput Molecular Platform for Antimicrobial Discovery and Study$417,235
R01 · FY2016 · AI · contact PI